# RNA-triggered innate immunity: friend and foe

**Authors:** Maike Henschel, Maria R. Conte, Rocio T. Martinez-Nunez

PMC · DOI: 10.3389/fgene.2026.1775625 · Frontiers in Genetics · 2026-02-23

## TL;DR

The paper explores how cells distinguish between self and foreign RNA to regulate immune responses, highlighting the role of RNA modifications and their impact on immunity and disease.

## Contribution

The paper provides a comprehensive overview of RNA sensing mechanisms and their implications for vaccine development.

## Key findings

- RNA chemical modifications and compartmentalization protect self RNA from immune sensing.
- Self RNA sensing can lead to immune pathologies when disrupted.
- Understanding RNA sensing has advanced the development of vaccines.

## Abstract

Endogenous, or ‘self’, vs. microbial, or ‘non-self’, RNA sensing can tip the scales between immune pathology and effective immunity. Cells are equipped to sense RNA, fundamental to trigger an innate immune response to clear viral infection that should not generate a harmful immune response against endogenous RNA. Multiple chemical modifications in RNA fine-tune its cellular sensing and are exploited by pathogens to evade immunity. Likewise, perturbations triggering self RNA sensing cause immune pathologies. This underscores the clinical need for a better understanding of self RNA recognition. Here, we address nucleic acid sensing in the innate immune response from an RNA-centric view. We discuss how self RNA is shielded from sensing by chemical modifications and subcellular compartmentalization, possible mechanisms and consequences of self-RNA sensing, and how this knowledge has been harnessed to revolutionize vaccine development.

## Full-text entities

- **Genes:** Ifih1 (interferon induced with helicase C domain 1) [NCBI Gene 71586] {aka 9130009C22Rik, Helicard, Hlcd, MDA5, RLR-2}, ZBP1 (Z-DNA binding protein 1) [NCBI Gene 81030] {aka C20orf183, DAI, DLM-1, DLM1}, TLR7 (toll like receptor 7) [NCBI Gene 51284] {aka IMD74, SLEB17, TLR7-like}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, EIF2AK2 (eukaryotic translation initiation factor 2 alpha kinase 2) [NCBI Gene 5610] {aka PKR, PPP1R83, PRKR}, PNPT1 (polyribonucleotide nucleotidyltransferase 1) [NCBI Gene 87178] {aka COXPD13, DFNB70, OLD35, PNPASE, SCA25, old-35}, CAP1 (cyclase associated actin cytoskeleton regulatory protein 1) [NCBI Gene 10487] {aka CAP, CAP1-PEN}, ADAR (adenosine deaminase RNA specific) [NCBI Gene 103] {aka ADAR1, AGS6, DRADA, DSH, DSRAD, G1P1}, XIST (X inactive specific transcript) [NCBI Gene 7503] {aka DXS1089, DXS399E, LINC00001, NCRNA00001, SXI1, swd66}, TLR3 (toll like receptor 3) [NCBI Gene 7098] {aka CD283, IIAE2, IMD83}, Mavs (mitochondrial antiviral signaling protein) [NCBI Gene 228607] {aka D430028G21Rik, IPS-1, Visa, cardif}, IFIT1 (interferon induced protein with tetratricopeptide repeats 1) [NCBI Gene 3434] {aka C56, G10P1, IFI-56, IFI-56K, IFI56, IFIT-1}, METTL3 (methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit) [NCBI Gene 56339] {aka IME4, M6A, MT-A70, Spo8, hMETTL3}, DHX58 (DExH-box helicase 58) [NCBI Gene 79132] {aka D11LGP2, D11lgp2e, LGP2, RLR-3}, Zbp1 (Z-DNA binding protein 1) [NCBI Gene 58203] {aka 2010010H03Rik, Dai, Dlm1, mZaDLM}, TLR8 (toll like receptor 8) [NCBI Gene 51311] {aka CD288, IMD98, TLR-8, hTLR8}, Adar (adenosine deaminase, RNA-specific) [NCBI Gene 56417] {aka Adar1, Adar1p110, Adar1p150, DRADA, mZaADAR}, CAP2 (cyclase associated actin cytoskeleton regulatory protein 2) [NCBI Gene 10486] {aka CMD2I}, IFIH1 (interferon induced with helicase C domain 1) [NCBI Gene 64135] {aka AGS7, Hlcd, IDDM19, IMD95, MDA-5, MDA5}, RIGI (RNA sensor RIG-I) [NCBI Gene 23586] {aka DDX58, RIG-I, RIG1, RLR-1, SGMRT2}, CMTR1 (cap methyltransferase 1) [NCBI Gene 23070] {aka FTSJD2, KIAA0082, MTr1, hMTr1}, Eif2ak2 (eukaryotic translation initiation factor 2-alpha kinase 2) [NCBI Gene 19106] {aka 2310047A08Rik, 4732414G15Rik, Pkr, Prkr, Tik}
- **Diseases:** lupus erythematosus (MESH:D008180), type I interferonopathies (MESH:D006969), autoimmune conditions (MESH:D001327), infection (MESH:D007239), cancer (MESH:D009369), immune disorders (MESH:D007154), COVID-19 (MESH:D000086382), death (MESH:D003643), brain injury (MESH:D001930), viral infection (MESH:D014777), AGS (MESH:C535607), chronic inflammation (MESH:D007249)
- **Chemicals:** ribose (MESH:D012266), lipids (MESH:D008055), monosaccharide (MESH:D009005), N1-methylpseudouridine (MESH:C013608), Pseudouridine (MESH:D011560), N6-methyladenosine (MESH:C010223), heparan sulfate (MESH:D006497), adenosine (MESH:D000241), 2'-O (-), inosine (MESH:D007288), 3-(3-amino-3-carboxypropyl) uridine (MESH:C006514)
- **Species:** Vesicular stomatitis virus (species) [taxon 11276], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12968011/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12968011/full.md

## References

114 references — full list in the complete paper: https://tomesphere.com/paper/PMC12968011/full.md

---
Source: https://tomesphere.com/paper/PMC12968011